News summary

Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study

Source: BioSpace - Funding • Published: 19 Nov 2026, 13:26

Summarized by Masters of Longevity from BioSpace - Funding.

CPRIT awarded $16.2 million to fund a Phase 2 trial of MT-601.

Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
Key Takeaways
  • The grant will fund a Phase 2 APOLLO study of MT-601.
  • Phase 1 showed 66% objective response and durable responses.
  • Safety data showed no dose-limiting toxicities or ICANS.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?